Literature DB >> 25282623

E-cadherin and CD10 expression in atypical hyperplastic and malignant endometrial lesions.

Ahmed R H Ahmed1, Eman M S Muhammad2.   

Abstract

BACKGROUND: Loss of E-cadherin is a critical step for development and progression of malignant tumors. CD10; a marker of non-neoplastic and neoplastic endometrial stroma, is associated with aggressiveness of many epithelial malignancies. AIMS: To evaluate expression and correlation of E-cadherin and CD10 in endometrial lesions and their possible role in differentiating atypical endometrial hyperplasia from endometrial carcinoma. The association of E-cadherin and CD10 expression with clinico-pathological parameters of endometrial carcinoma was also investigated.
MATERIALS AND METHODS: Fifty four cases including 28 endometrial carcinomas; 19 endometrial hyperplasia and 7 cases of normal endometrial changes were enrolled for this study. The expression of E-cadherin and CD10 was evaluated by immunohistochemistry using the streptavidin-biotin technique.
RESULTS: There was a strong association between malignant change of endometrial glands and membrano-cytoplasmic localization of E-cadherin (p<0.001). Expression of E-cadherin but not CD10 was significantly higher in endometrial carcinomas compared to atypical endometrial hyperplasia (p<0.01). Expression of E-cadherin was not associated with CD10 expression in different endometrial lesions. High grade tumors expressed low levels of both E-cadherin (p<0.01) and CD10 (p<0.05) and serous endometrial carcinoma had low E-cadherin and CD10 expression compared to endometrioid carcinoma (p<0.01 and <0.05, respectively). Expression of both molecules showed no association with depth of tumor invasion or FIGO stage. Tumors with lower E-cadherin or CD10 expression had higher rates of vascular tumor emboli (p<0.01 and <0.07, respectively).
CONCLUSIONS: Although expression of E-cadherin and CD10 in endometrial lesions was not correlated, reduced expression of both molecules could be critical for progression of endometrial carcinoma.
Copyright © 2014. Production and hosting by Elsevier B.V.

Entities:  

Keywords:  CD10; E-cadherin; Endometrial carcinoma; FIGO stage; Vascular tumor emboli

Mesh:

Substances:

Year:  2014        PMID: 25282623     DOI: 10.1016/j.jnci.2014.08.002

Source DB:  PubMed          Journal:  J Egypt Natl Canc Inst        ISSN: 1110-0362


  3 in total

Review 1.  New concepts for an old problem: the diagnosis of endometrial hyperplasia.

Authors:  Peter A Sanderson; Hilary O D Critchley; Alistair R W Williams; Mark J Arends; Philippa T K Saunders
Journal:  Hum Reprod Update       Date:  2017-03-01       Impact factor: 15.610

2.  SOX17 Inhibits Tumor Metastasis Via Wnt Signaling In Endometrial Cancer.

Authors:  Weiqiang Zhou; Kai Wang; Jingyun Wang; Junjie Qu; Guiqiang Du; Yongli Zhang
Journal:  Onco Targets Ther       Date:  2019-10-07       Impact factor: 4.147

3.  Expression level of E-, N- and P-cadherin proteins in endometrial cancer.

Authors:  Łukasz Lewczuk; Anna Pryczynicz; Katarzyna Guzińska-Ustymowicz
Journal:  Oncol Lett       Date:  2021-02-04       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.